Background: Docetaxel is one of the most promising new drugs against squamous-cell carcinoma of the head and neck (SCCHN), while cisplatin is one of the most active single agents. A phase I study has shown the feasibility of the combination of the two drugs, and activity in SCCHN has been seen.
Introduction
Squamous-cell carcinoma of the head and neck (SCCHN) often presents as a locoregional disease, for which the role of chemotherapy is being considered increasingly, in particular when administered in alternation with radiotherapy [1] . On the other hand, the role of induction chemotherapy prior to local therapy is less clearly defined, but positive results have been reported [2] .
The choice of the induction chemotherapy regimen represents a challenge. Cisplatin (CDDP) is one of the most active single agents against SCCHN; in fact, response rates in recurrent disease average approximately 17%, varying from 0% to 41% [3] . Docetaxel is one of the most promising new drugs against SCCHN, and it is able to induce response rates ranging between 21% and 42% [4, 5] . A phase I study has tested the feasibility of the combination docetaxel-cisplatin, and has shown activity in SCCHN, since three out of four patients achieved a partial response [6] . Based on the above observations, we started a phase II study of docetaxel and cisplatin in patients with locally advanced or metastatic SCCHN.
Patients and methods

Patient selection
Eligibility criteria for study entry included pathologically confirmed, unresectable, locally advanced or metastatic SCCHN: at least one bidimensionally measurable lesion: age > 18 <75 years: Eastern Cooperative Oncology Group (ECOG) performance status 0-2; adequate bone marrow, liver and renal function: life expectancy of at least three months. Patients were ineligible if they had received prior radiotherapy or chemotherapy. Pregnancy, uncontrolled infection, cerebral melastases, concurrent or previous malignancy, severe neurologic disease, a history of congestive heart failure, and severe coronary heart disease were also exclusion criteria. The study was approved by the Ethics Committee of each participating center, and written informed consent was obtained from each patient.
Treatment plan
Patients received docetaxel at a dose of 75 mg/m 2 over one hour, followed by hydration with 1000 ml normal saline (three hour i.v). and then by CDDP at the dose of 100 mg/m 2 . diluted in 500 ml of normal saline solution, over three hours Vigorous posthydration (1000 ml) then followed. 5-HTj blocking agents were used as antiemetic coverage. Premedication with prednisone at the dose of 50 mg orally was given 13 hours. 7 hours, and I hour before docetaxel administration, and then twice a day for 2 days following docetaxel administration. Treatment was recycled every 21 days and withheld for I week (until day 28). if neutrophil count was <1500/ul, platelet count was < 100,000/ul, or any other toxicity exceeded grade 1 at the time of chemotherapy recycling. If full recovery of toxicity did not occur within two weeks, treatment was discontinued. In case of grade 4 neutropenia lasting more than seven days, or febrile neutropenia. occurring at nadir, even after full recovery, drugs were administered with a reduction to 75% of the planned dose over subsequent courses. If further febrile neutropenia occurred even with this dose reduction, the patient was taken oil'study. Docetaxel and CDDP doses were reduced to 75% when grade 3 vomiting, or grade 3 diarrhea, or grade 2 peripheral neuropathy occurred. CDDP dose was reduced to 75 mg/m 2 when creatinine clearance was between 45 and 55 ml/min; if creatinine clearance was <45 ml/min. treatment would have to continue with docetaxel alone. Granulocyte colony-stimulating factor (G-CSF) was permitted in patients with grade 4 neutropenia lasting more than seven days and febrile neutropenia. Furthermore, prophylactic administration of G-CSF was allowed in subsequent cycles in patients who had experienced short-lasting grade 4 neutropenia.
Patient evaluation
At enrollment, patients were evaluated by a complete history and physical examination, performance status recording, complete bloodcell (CBC) count, serum chemistries, unnalysis, ECG. chest X-ray. thoracic and cervical computed tomography scan (CT) or magnetic resonance imaging (MRI), abdomen ultrasonography. bone scan. upper aerodigestive tract endoscopy. Other exams were performed only in the presence of a clinical indication. Patients were monitored weekly throughout treatment by CBC count and a complete biochemistry profile Evaluation for tumour response was performed after three courses of chemotherapy, with repetition of all the tests that were abnormal at baseline, plus additional tests where clinically indicated. Response was assessed according to standard WHO criteria. A followup scan obtained at least four weeks later was required to confirm complete response (CR) or partial response (PR). After three courses of chemotherapy, responsive metastatic patients received additional treatment up to complete response, progressive disease, or excessive toxicity; patients with locally advanced disease were to undergo radiation therapy, which was started within five weeks of the last cycle of chemotherapy and was given in daily fractions of 2.0 Grays (Gy). Wide treatment fields were planned to encompass the primary tumour and involved neck nodes, and a total dose of 52 Gy was reached in all cases. A boost to the primary tumour bed. which received 64-70 Gy, followed thereafter. Toxicity was graded according to the NCI Common Toxicity Criteria (CTC).
Statistical methods
This study had a two-stage design, with 15 eligible patients to be enrolled during the first stage. If five or more objective responses were observed, then an additional 31 eligible patients would be accrued Such a design would have an 80% power to detect an objective response rate of 50% rather than 30% Duration of partial response or no change was calculated from the time of study entry to the first evidence of disease progression. Duration of complete response was calculated from its first documentation to the first evidence of disease progression. Survival was determined from the time of study entry to the time 
Results
Patient characteristics
Between June 1997 and January 1999, 46 patients were entered onto the study. Fifteen/forty-six patients had relapsed after previous surgery, while thirty-one patients had never had any kind of treatment for their tumour. Only 1 patient had lung metastases at the time of study entry, while the remaining 45 patients had locoregionally advanced disease. Patient characteristics are detailed in Table 1 .
Response, locoregional treatment, and survival
A total of 126 courses of chemotherapy were administered, for a median number of 3 courses per patient (range 1-7). Ten patients did not complete three courses of chemotherapy because of early death; one patient discontinued treatment after one course. These cases were considered as treatment failures, according to intention to treat analysis. Five CRs (11%; 95% CI: 4%-24%) and 16 PRs (35%; 95% CI: 21%-50%) were observed in 46 patients, for an overall response rate of 46% (95% CI: 31%-61%). Twenty-five patients were considered treatment failures, including eight patients who had disease stabilization, six patients with progressive disease, and eleven patients who did not complete chemotherapy. At the end of the planned courses of chemotherapy, responsive and stable patients with locoregionally advanced disease were offered radiation therapy. Five patients refused radiotherapy, while two patients were lost to follow-up after completion of radiotherapy and could not be reevaluated. Following induction chemotherapy plus radiation therapy, 9 of 21 evaluable patients were rendered disease free, while 8 additional patients had a PR, for an overall response rate of 81% (95% CI: 58%-95%) for the combined approach. However, according to intention to treat analysis, the overall response rate for the combined approach in patients with locally advanced disease was 17 of 45 (38%, 95% CI: 24%-53%). After a median follow-up of 18 months, the median duration of response was 12 months (range 3-25+), and the median overall survival was 11 months (Figure 1 ).
Toxicity
Of the 126 courses, eight were administered with a 25% docetaxel dose reduction, and 11 with a 25% cisplatin dose reduction, because of toxicity during previous cycles. In two courses cisplatin administration was omitted because of worsened renal function. Mean actually delivered dose intensities of docetaxel and cisplatin were 94%, and 92% of the planned, respectively. Ten patients died before completion of the planned three courses of chemotherapy. This was considered possibly treatment-related in six cases (sepsis following grade 4 neutropenia in two cases, hypovolemic shock following severe diarrhea in four cases). In the other four cases, one patient died after the first course of treatment because of a massive haemorrhage from the primary tumour; one patient had a stroke seven days after first course of treatment, one had an acute respiratory insufficiency due to tracheostomy problems, one patient had an unexplained sudden death. As expected, neutropenia was the most severe side-effect. Twenty-eight patients had grade 3 or 4 neutropenia, which was complicated by fatal sepsis in two cases. Median duration of neutropenia was four days (range 2-7). G-CSF was administered subcutaneously for a 
anaemia was observed in four patients only, while grade 3-4 thrombocytopenia was observed in three patients. Diarrhea was the most troublesome among nonhaematologic toxicities. Four patients had grade 4 diarrhea, which was in all cases complicated by severe dehydration and electrolytic imbalance leading to patient death. Grade 4 vomiting was observed in three patients, grade 4 liver toxicity occurred in one patient, but was promptly reversible. Full details on observed toxicity are shown in Table 2 .
Discussion
The search of new active anticancer drugs in SCCHN is a strongly pursued effort. Docetaxel ranks among the most active new agents [4, 5] , and can be usefully combined with cisplatin, due to the different mechanism of action of the two drugs, and the partly non overlapping toxicity profiles. After the phase 1 study which first tested the combination of docetaxel and cisplatin also showed activity in SCCHN, a number of phase II studies in locally advanced, and /or recurrent, and/or metastatic SCCHN have been undertaken.
Only two of these studies have been published thus far. In the first study, carried out by the EORTC Early Clinical Studies Group [7] , docetaxel was given at 100 mg/m 2 and cisplatin at 75 mg/m 2 every three weeks. Prior neoadjuvant cisplatin-based chemotherapy and prior radiotherapy were allowed in this study. The overall response rate in this study was 53.7%, and toxicity was relevant. In fact, reversible myelosuppression occurred in 80% of all cycles and was complicated by neutropenic fever in 10 cases; 1 treatment-related death occurred (neutropenic sepsis and pneumonia). However, although patient population was more heavily pretreated than in our study, and G-CSF was not used, the difference in treatment-related mortality between our study and EORTC study is quite remarkable. Specht et al. have recently published a phase II study of docetaxel and cisplatin, both used at 75 mg/m 2 every three weeks, in recurrent or disseminated SCCHN [8] . This study also allowed prior radiotherapy. A 33% objective response rate was achieved in 25 patients; median survival was 11 months. Toxicity was remarkable in this study as well, although less severe than in our study, since one toxic death occurred (neutropenia and infection), three patients discontinued treatment early, and grade 3-4 neutropenia occurred in 75% of patients. Other studies which test the combination of docetaxel-cisplatin in SCCHN are ongoing. Mel et al. [9] have achieved a 55% overall response rate in 37 evaluable patients, with no toxic deaths and mild extrahaematologic toxicity. Forastiere et al. [10] have achieved a 52% overall response rate in 33 patients, with one possibly treatment-related early death, and mainly haematologic toxicity. Baur et al. [11] have obtained a 73% response rate, but 4 early deaths in 35 patients. All but one of these studies included patients with recurrent disease after radiotherapy. In the first two of the above studies, docetaxel and cisplatin were used at the dose of 75 mg/m 2 each, while in the last one docetaxel was given at 80 mg/m 2 and cisplatin at 70 mg/m 2 .
Neutropenia and diarrhea represented the most troublesome toxicities in our study and their complications caused the observed toxic deaths. Overall, although toxic deaths have been reported in nearly all docetaxelcisplatin studies, toxicity was more remarkable in our study than in the others, and this might be related to the higher cisplatin dose.
In our study, 21 of 46 patients (46%) achieved an objective response. Median duration of response was 12 months, while median survival was 11 months. Overall, the outcome of this trial in terms of antitumour activity looks quite disappointing, and is certainly not better than that observed with conventional regimens; this holds true not only for response rate, but for survival as well.
The high number of toxic deaths seems to raise concern about the feasibility of this drug combination. However, it has to be remarked that in all fatal events there was a delay in referral of patient symptoms to the investigator, so that prompt institution of treatment could not be applied. The very low social and cultural background of the average SCCHN patient in the areas where the study was undertaken may explain the reason of this behavior and points to early referral to physician in case of toxicity, as a major determinant of the outcome. Future studies will have to clarify whether the incorporation of docetaxel within standard cisplatin plus 5-fluorouracil (5-FU) regimens, possibly with a lower cisplatin dose, is feasible. Phase I-II trials are addressing this issue [12] and a phase III study comparing docetaxel-cisplatin-5-FU with standard treatment has been started.
